VALBIOTIS
29.3.2022 07:37:05 CEST | Business Wire | Press release
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070 against hypercholesterolemia.
This innovative protocol, involving 10 healthy volunteers, has first confirmed the presence of 22 metabolites2 of interest in the serum3 of volunteers. The analyses were conducted following oral administration of the clinical dose of 5g of TOTUM•070, used also in the Phase II HEART study. Most of the 22 metabolites are already known for their activity on metabolism. Mode of action analyses then demonstrated, among other things, two effects of TOTUM•070 on human liver cells: inhibition of the cholesterol synthesis pathway and inhibition of cholesterol storage in hepatocytes. These two effects on cholesterol in the liver, which is one of the main metabolic organs, speak in favor of TOTUM•070’s potential against hypercholesterolemia. Following on from these positive results, Valbiotis will announce the outcome of its Phase II HEART clinical efficacy study in the second quarter of 2022, as planned. Its primary endpoint is the reduction of blood LDL-cholesterol.
Pascal SIRVENT, Director of Discovery and Preclinical and Translational Research and Member of the Board of Directors, states: “For the first time, this clinical study has evaluated the bioavailability and hepatic mode of action of TOTUM•070 in humans. The results live up to our expectations: we can confirm that TOTUM•070 contains many metabolites of interest for regulating cholesterol. Most importantly, the results show that these metabolites are bioavailable in humans and have two significant effects on the regulation of cholesterol in the cells of the human liver, one of the main metabolic organs. These novel clinical data build on the positive preclinical results presented in 2021 and pave the way for further mode-of-action investigations in the liver. Above all, they confirm the potential of TOTUM•070 against hypercholesterolemia in humans, pending the imminent results of our Phase II clinical efficacy study.”
Murielle CAZAUBIEL, Director of Medical, Regulatory and Industrial Affairs and Member of the Board of Directors, adds: “During this clinical study on TOTUM•070, we used an innovative methodology adapted to our plant-based active substances that combines metabolomics and mode of action, which is now producing results. This is a positive clinical development and a very encouraging sign while we wait for the Phase II HEART clinical efficacy results, which will become available in the second quarter of 2022.”
Results of the clinical study on bioavailability and mode of action
This study was conducted on 10 healthy volunteers in an open-label setting and followed a protocol combining metabolomics and mode of action, designed and implemented by Clinic’n’Cell. Professor Gisèle PICKERING, coordinator of the Clinical Investigation Center of the Clermont-Ferrand University Hospital, was Principal Investigator4 .
Metabolomic analysis consists of characterizing the metabolites of an active substance in serum, i.e., the molecules derived from this active substance following their intestinal absorption and passage into the blood. After a single oral dose of 5g of TOTUM•070, which is the clinical daily dose, used also in the HEART clinical study (see below), analysis of the volunteers’ serum confirmed the presence of 22 metabolites of interest, the majority of which are known to have a biological activity on metabolism. Kinetic measurements validated good bioavailability of these metabolites in serum within three hours of oral TOTUM•070 intake.
In a second step, the serum collected from volunteers after oral intake of 5g of TOTUM•070 – a serum rich in active metabolites from TOTUM•070 – was used to conduct in vitro tests on human liver cells exposed to massive lipid intake. In this context of “lipotoxic stress”, the volunteers’ serum exerted two major effects on these human liver cell lines: inhibition of the de novo cholesterol synthesis pathway1 and inhibition of cholesterol storage. It also showed no toxicity.
All analyses were conducted with a double control: cell cultures with and without lipotoxic stress, then with and without serum enriched in active metabolites.
Upcoming publication of the Phase II clinical results of TOTUM•070 on hypercholesterolemia
The Phase II HEART clinical trial results will be announced in the second quarter of 2022. This multi-center study will evaluate the efficacy of TOTUM•070 in reducing blood LDL-cholesterol levels versus placebo, in 120 volunteers with mild to moderate untreated hypercholesterolemia. These results will be decisive for the marketing of TOTUM•070, an innovative 100% plant-based active substance containing neither phytosterols nor red yeast rice, and for its positioning as a reference non-drug option against LDL-cholesterol.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN Code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com
).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1
Cholesterol can be brought by food or produced by the body itself ("de novo
synthesis").
2
Molecules derived from TOTUM•070, following their intestinal absorption and passage into the blood.
3
The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in clotting) have been removed.
4
ID-RCB: 2021-A01211-40
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005495/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press release
The Company will highlight its opportunities and unique solutions in enterprise software support and its ownership of the Agentic AI ERP market, present its sales strategy and financial model and host a panel discussion featuring Rimini Street global clients from a variety of industries Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
